Vertex Pharmaceuticals Incorporated Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Subordinated Notes

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it intends to offer, subject to market and other conditions, 6,000,000 shares of its common stock in an underwritten public offering under an automatically effective shelf registration statement on file with the Securities and Exchange Commission. Vertex intends to grant the underwriters an over-allotment option to purchase up to an additional 900,000 shares of its common stock.